Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.
The firm said that it expects to report a 12 percent year-over-year increase in molecular diagnostics product revenues, driven by Verigene and Aries placements.
